AR007767A1 - Nuevos derivados de acidos alfa-hidroxi, su preparacion y utilizacion de dichos derivados o fragmentos de los mismos como antagonistas de receptores de las endotelinas - Google Patents

Nuevos derivados de acidos alfa-hidroxi, su preparacion y utilizacion de dichos derivados o fragmentos de los mismos como antagonistas de receptores de las endotelinas

Info

Publication number
AR007767A1
AR007767A1 ARP970101460A ARP970101460A AR007767A1 AR 007767 A1 AR007767 A1 AR 007767A1 AR P970101460 A ARP970101460 A AR P970101460A AR P970101460 A ARP970101460 A AR P970101460A AR 007767 A1 AR007767 A1 AR 007767A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
group
derivatives
hydroxy
Prior art date
Application number
ARP970101460A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR007767A1 publication Critical patent/AR007767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/38—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se trata de derivados de ácidos alfa-hidroxicarboxílicos de fórmula (I) donde R es un grupo de fórmula-CO-R1, en la cual R1 tiene los siguientessignificados: a) hidrógeno, b) un grupo succinilimidoxi; c) un grupo heteroaromático de 5m iembros ligados mediante un átomo de nitrógeno, tal comopirrolilo, pirazolilo, imidazolilo o triazolilo, opcionalmente sustituído por uno o dos átomos de halógeno o uno o dos grupos alquilo de 1 a 4 átomos decarbono o uno o dos grupos alcoxi de1 a 4 átomos de carbono; d) un grupo de fórmula (II) en el cual k vale 0, 1 y 2 y p es 1,2,3 y 4, y R9 es C1-C4-alquilo, C3-C7-cicloalquilo, C3-C6-alquenilo, C3-C6 alquinilo o fenilo eventualmente sustituído, con al menos uno de los siguientesradi cales: halógeno, nitro,ciano, C1-C4-alquilo, C1-C4 halogenoalquilo, hidroxi C1-C4-alcoxi, C1-C4- -alquiltio, mercapto, amino, C1-C4-alquilo, C1-C4 dialquilamino; e) R1 tambiénpuede ser un radical OR10, representando R10 alguno de lossiguientes : hidrógeno, el catión de un metal alcalino tal como litio, sodio, potasio, o elcatión de un metal alcalio-térreo tal como calcio, magnesio o bario como también ión alquilamonio o amonio fisiológiamente tolerable; C3-C8cicloalquiloC1 -C8-alquilo, CH2-fenilo, que puede estar sustituido por uno o más de los siguientes radicales: halógeno, nitro, ciano, C1-C4-alquilo, C1-C4-halogenoalquilo, hidroxi, C1-C4-alcoxi, C1-C4-alcoxi, mercapto, C1-C4-alquiltío amino, C1-C4 alquilamino, C1-C4-dialquilamino; un grupo C3-C6-alquenilo o ungrupo C3-C6-alquinilo, pudiendo por su parte estos grupos llevar de uno a cinco átomos de halógeno; R10 puede también ser un radical fenilo, que puede llevarde uno a cinco átomos dehalógeno y/o de u no a tres de los siguientes radicales: nitro, ciano, C1-C4-alquilo, C1-C4-halogenoalquilo, hidroxi, C1-C4-alcoxi,
ARP970101460A 1996-04-12 1997-04-11 Nuevos derivados de acidos alfa-hidroxi, su preparacion y utilizacion de dichos derivados o fragmentos de los mismos como antagonistas de receptores de las endotelinas AR007767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19614533A DE19614533A1 (de) 1996-04-12 1996-04-12 Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
AR007767A1 true AR007767A1 (es) 1999-11-24

Family

ID=7791117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101460A AR007767A1 (es) 1996-04-12 1997-04-11 Nuevos derivados de acidos alfa-hidroxi, su preparacion y utilizacion de dichos derivados o fragmentos de los mismos como antagonistas de receptores de las endotelinas

Country Status (25)

Country Link
US (1) US6686369B1 (es)
EP (1) EP0892787B1 (es)
JP (1) JP2000508326A (es)
KR (1) KR20000005369A (es)
AR (1) AR007767A1 (es)
AT (1) ATE242770T1 (es)
AU (1) AU731579B2 (es)
BG (1) BG102868A (es)
BR (1) BR9708608A (es)
CA (1) CA2250757A1 (es)
CO (1) CO4900040A1 (es)
DE (2) DE19614533A1 (es)
HR (1) HRP970198A2 (es)
HU (1) HUP9901312A3 (es)
ID (1) ID16501A (es)
IL (1) IL126350A0 (es)
NO (1) NO311801B1 (es)
NZ (1) NZ332096A (es)
PL (1) PL329241A1 (es)
SK (1) SK134498A3 (es)
TR (1) TR199802039T2 (es)
TW (1) TW425383B (es)
UA (1) UA49884C2 (es)
WO (1) WO1997038981A1 (es)
ZA (1) ZA973097B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL334014A1 (en) * 1996-12-18 2000-01-31 Basf Ag Heterocyclic derivatives of carboxylic acids, their preduction and application as antagonists of endothelin receptors
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
KR100523112B1 (ko) 1997-10-17 2005-10-19 유로진 리미티드 레닌-안지오텐신계 억제제의 사용
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
PL1781276T3 (pl) 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
US20110046163A1 (en) * 2009-08-20 2011-02-24 Moore Ii Bob M Furanopyrimidine cannabinoid compounds and related methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4035758A1 (de) 1990-11-08 1992-05-14 Schering Ag Substituierte (alpha)-pyrimidinyloxy(thio)- und (alpha)-triazinyloxy(thio)-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4411225A1 (de) 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
ATE242770T1 (de) 2003-06-15
AU731579B2 (en) 2001-04-05
PL329241A1 (en) 1999-03-15
BR9708608A (pt) 1999-08-03
EP0892787B1 (de) 2003-06-11
CO4900040A1 (es) 2000-03-27
KR20000005369A (ko) 2000-01-25
US6686369B1 (en) 2004-02-03
HRP970198A2 (en) 1998-04-30
DE59710272D1 (de) 2003-07-17
DE19614533A1 (de) 1997-10-16
EP0892787A1 (de) 1999-01-27
HUP9901312A3 (en) 2000-06-28
NO984717D0 (no) 1998-10-09
IL126350A0 (en) 1999-05-09
NO311801B1 (no) 2002-01-28
TW425383B (en) 2001-03-11
CA2250757A1 (en) 1997-10-23
WO1997038981A1 (de) 1997-10-23
NZ332096A (en) 2000-01-28
HUP9901312A2 (hu) 1999-08-30
SK134498A3 (en) 1999-03-12
AU2636597A (en) 1997-11-07
BG102868A (bg) 1999-11-30
JP2000508326A (ja) 2000-07-04
UA49884C2 (uk) 2002-10-15
ZA973097B (en) 1998-10-12
TR199802039T2 (xx) 1999-01-18
NO984717L (no) 1998-10-09
ID16501A (id) 1997-10-02

Similar Documents

Publication Publication Date Title
AR007767A1 (es) Nuevos derivados de acidos alfa-hidroxi, su preparacion y utilizacion de dichos derivados o fragmentos de los mismos como antagonistas de receptores de las endotelinas
WO2003084936A3 (en) Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
EA199700416A1 (ru) Бициклические амины и их применение в качестве инсектицидов
ES8702907A1 (es) Procedimiento para la obtencion de acidos 7-amino-1-ciclopropil-6,8-dihalogeno-1,4-dihidro-4-oxo-3-quinolincarboxilico
NO954571L (no) Sialyl-LeX-analoger som inhibitorer av cellulær adhesjon
AR247559A1 (es) Composicion herbicida y un compuesto derivado de 1, 3, 5-triazinas 2, 4, 6-trisustituidas, procedimiento para prepararlo, su empleo y el metodo para combatir el crecimiento de plantas no deseadas
ATE409168T1 (de) Kristalline zeolithische aluminosilikat- zusammensetzung:uzm-4m
CO4770961A1 (es) Nuevos derivados de aminoacido y su obtencion
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
AR240796A2 (es) Procedimiento para la preparacion de alcoholes aromaticos tio substituidos y compuesto intermediarioutilizado en el mismo
AR245933A1 (es) Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales.
ES476658A1 (es) Procedimiento para preparar derivados de sulfonamido-piridi-na
TR200000993T2 (tr) Endotelin antagonistleri.
ATE296300T1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE69918465D1 (de) Sulfonamidhydroxamate
BRPI0616186A2 (pt) derivado de 4-fenil-6-substituìdo-pirimidina-2-carbonitrila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um derivado de 4-fenil-6-substituìdo-pirimidina-2-carbonitrila
CO4900038A1 (es) Nuevos derivados de acidos carboxilicos, su obtencion y aplicacion
EA199801013A1 (ru) Производные дистамицина, способ их получения и применение в качестве противоопухолевых и противовирусных агентов
CO4900039A1 (es) Nuevos derivados de acidos carboxilicos, su obtencion y aplicacion
CA2117610A1 (en) Indole derivatives as steroid 5 alpha-reductase inhibitors
AR000795A1 (es) Derivados de piridina y pirimidina, procedimiento e intermediarios para prepararlos, composicion herbicida que los comprende, metodo para combatir con los mismos el crecimiento de plantas indeseadas, y uso de dichos derivados para controlar el crecimiento de plantas indeseadas
KR920002536A (ko) 피롤 유도체
ATE212036T1 (de) Lactol-derivate, als cathepsin l inhibitoren
NO944121L (no) Epoksyravsyrederivater
ES8606236A1 (es) Un procedimiento para la preparacion de un compuesto de calixareno.

Legal Events

Date Code Title Description
FC Refusal